miR-137 is a tumor suppressor in endometrial cancer and is repressed by DNA hypermethylation

Wei Zhang, Jo Hsin Chen, Tianjiao Shan, Irene Aguilera-Barrantes, Li Shu Wang, Hui-ming Huang, Janet S. Rader, Xiugui Sheng, Yi Wen Huang

Research output: Contribution to journalArticle

7 Citations (Scopus)

Abstract

Endometrial cancer is the most common gynecological cancer in the United States. We wanted to identify epigenetic aberrations involving microRNAs (miRNAs), whose genes become hypermethylated in endometrial primary tumors. By integrating known miRNA sequences from the miRNA database (miRBase) with DNA methylation data from methyl-CpG-capture sequencing, we identified 111 differentially methylated regions (DMRs) associated with CpG islands (CGIs) and miRNAs. Among them, 22 DMRs related to 29 miRNAs and within 8 kb of CGIs were hypermethylated in endometrial tumors but not in normal endometrium. miR-137 was further validated in additional endometrial primary tumors. Hypermethylation of miR-137 was found in both endometrioid and serous endometrial cancer (P < 0.01), and it led to the loss of miR-137 expression. Treating hypermethylated endometrial cancer cells with epigenetic inhibitors reactivated miR-137. Moreover, genetic overexpression of miR-137 suppressed cancer cell proliferation and colony formation in vitro. When transfected cancer cells were implanted into nude mice, the cells that overexpressed miR-137 grew more slowly and formed smaller tumors (P < 0.05) than vector transfectants. Histologically, xenograft tumors from cancer cells expressing miR-137 were less proliferative (P < 0.05), partly due to inhibition of EZH2 and LSD1 expression (P < 0.01) in both the transfected cancer cells and tumors. Reporter assays indicated that miR-137 targets EZH2 and LSD1. These results suggest that miR-137 is a tumor suppressor that is repressed in endometrial cancer because the promoter of its gene becomes hypermethylated.

Original languageEnglish (US)
Pages (from-to)1-11
Number of pages11
JournalLaboratory Investigation
DOIs
StateAccepted/In press - Jun 28 2018

Fingerprint

Endometrial Neoplasms
DNA
Neoplasms
MicroRNAs
CpG Islands
Epigenomics
DNA Methylation
Endometrium
Heterografts
Nude Mice
Genes
Cell Proliferation
Databases

ASJC Scopus subject areas

  • Pathology and Forensic Medicine
  • Molecular Biology
  • Cell Biology

Cite this

Zhang, W., Chen, J. H., Shan, T., Aguilera-Barrantes, I., Wang, L. S., Huang, H., ... Huang, Y. W. (Accepted/In press). miR-137 is a tumor suppressor in endometrial cancer and is repressed by DNA hypermethylation. Laboratory Investigation, 1-11. https://doi.org/10.1038/s41374-018-0092-x

miR-137 is a tumor suppressor in endometrial cancer and is repressed by DNA hypermethylation. / Zhang, Wei; Chen, Jo Hsin; Shan, Tianjiao; Aguilera-Barrantes, Irene; Wang, Li Shu; Huang, Hui-ming; Rader, Janet S.; Sheng, Xiugui; Huang, Yi Wen.

In: Laboratory Investigation, 28.06.2018, p. 1-11.

Research output: Contribution to journalArticle

Zhang, W, Chen, JH, Shan, T, Aguilera-Barrantes, I, Wang, LS, Huang, H, Rader, JS, Sheng, X & Huang, YW 2018, 'miR-137 is a tumor suppressor in endometrial cancer and is repressed by DNA hypermethylation', Laboratory Investigation, pp. 1-11. https://doi.org/10.1038/s41374-018-0092-x
Zhang, Wei ; Chen, Jo Hsin ; Shan, Tianjiao ; Aguilera-Barrantes, Irene ; Wang, Li Shu ; Huang, Hui-ming ; Rader, Janet S. ; Sheng, Xiugui ; Huang, Yi Wen. / miR-137 is a tumor suppressor in endometrial cancer and is repressed by DNA hypermethylation. In: Laboratory Investigation. 2018 ; pp. 1-11.
@article{80d462c8de22404a9de25a6b4af3b440,
title = "miR-137 is a tumor suppressor in endometrial cancer and is repressed by DNA hypermethylation",
abstract = "Endometrial cancer is the most common gynecological cancer in the United States. We wanted to identify epigenetic aberrations involving microRNAs (miRNAs), whose genes become hypermethylated in endometrial primary tumors. By integrating known miRNA sequences from the miRNA database (miRBase) with DNA methylation data from methyl-CpG-capture sequencing, we identified 111 differentially methylated regions (DMRs) associated with CpG islands (CGIs) and miRNAs. Among them, 22 DMRs related to 29 miRNAs and within 8 kb of CGIs were hypermethylated in endometrial tumors but not in normal endometrium. miR-137 was further validated in additional endometrial primary tumors. Hypermethylation of miR-137 was found in both endometrioid and serous endometrial cancer (P < 0.01), and it led to the loss of miR-137 expression. Treating hypermethylated endometrial cancer cells with epigenetic inhibitors reactivated miR-137. Moreover, genetic overexpression of miR-137 suppressed cancer cell proliferation and colony formation in vitro. When transfected cancer cells were implanted into nude mice, the cells that overexpressed miR-137 grew more slowly and formed smaller tumors (P < 0.05) than vector transfectants. Histologically, xenograft tumors from cancer cells expressing miR-137 were less proliferative (P < 0.05), partly due to inhibition of EZH2 and LSD1 expression (P < 0.01) in both the transfected cancer cells and tumors. Reporter assays indicated that miR-137 targets EZH2 and LSD1. These results suggest that miR-137 is a tumor suppressor that is repressed in endometrial cancer because the promoter of its gene becomes hypermethylated.",
author = "Wei Zhang and Chen, {Jo Hsin} and Tianjiao Shan and Irene Aguilera-Barrantes and Wang, {Li Shu} and Hui-ming Huang and Rader, {Janet S.} and Xiugui Sheng and Huang, {Yi Wen}",
year = "2018",
month = "6",
day = "28",
doi = "10.1038/s41374-018-0092-x",
language = "English (US)",
pages = "1--11",
journal = "Laboratory Investigation",
issn = "0023-6837",
publisher = "Nature Publishing Group",

}

TY - JOUR

T1 - miR-137 is a tumor suppressor in endometrial cancer and is repressed by DNA hypermethylation

AU - Zhang, Wei

AU - Chen, Jo Hsin

AU - Shan, Tianjiao

AU - Aguilera-Barrantes, Irene

AU - Wang, Li Shu

AU - Huang, Hui-ming

AU - Rader, Janet S.

AU - Sheng, Xiugui

AU - Huang, Yi Wen

PY - 2018/6/28

Y1 - 2018/6/28

N2 - Endometrial cancer is the most common gynecological cancer in the United States. We wanted to identify epigenetic aberrations involving microRNAs (miRNAs), whose genes become hypermethylated in endometrial primary tumors. By integrating known miRNA sequences from the miRNA database (miRBase) with DNA methylation data from methyl-CpG-capture sequencing, we identified 111 differentially methylated regions (DMRs) associated with CpG islands (CGIs) and miRNAs. Among them, 22 DMRs related to 29 miRNAs and within 8 kb of CGIs were hypermethylated in endometrial tumors but not in normal endometrium. miR-137 was further validated in additional endometrial primary tumors. Hypermethylation of miR-137 was found in both endometrioid and serous endometrial cancer (P < 0.01), and it led to the loss of miR-137 expression. Treating hypermethylated endometrial cancer cells with epigenetic inhibitors reactivated miR-137. Moreover, genetic overexpression of miR-137 suppressed cancer cell proliferation and colony formation in vitro. When transfected cancer cells were implanted into nude mice, the cells that overexpressed miR-137 grew more slowly and formed smaller tumors (P < 0.05) than vector transfectants. Histologically, xenograft tumors from cancer cells expressing miR-137 were less proliferative (P < 0.05), partly due to inhibition of EZH2 and LSD1 expression (P < 0.01) in both the transfected cancer cells and tumors. Reporter assays indicated that miR-137 targets EZH2 and LSD1. These results suggest that miR-137 is a tumor suppressor that is repressed in endometrial cancer because the promoter of its gene becomes hypermethylated.

AB - Endometrial cancer is the most common gynecological cancer in the United States. We wanted to identify epigenetic aberrations involving microRNAs (miRNAs), whose genes become hypermethylated in endometrial primary tumors. By integrating known miRNA sequences from the miRNA database (miRBase) with DNA methylation data from methyl-CpG-capture sequencing, we identified 111 differentially methylated regions (DMRs) associated with CpG islands (CGIs) and miRNAs. Among them, 22 DMRs related to 29 miRNAs and within 8 kb of CGIs were hypermethylated in endometrial tumors but not in normal endometrium. miR-137 was further validated in additional endometrial primary tumors. Hypermethylation of miR-137 was found in both endometrioid and serous endometrial cancer (P < 0.01), and it led to the loss of miR-137 expression. Treating hypermethylated endometrial cancer cells with epigenetic inhibitors reactivated miR-137. Moreover, genetic overexpression of miR-137 suppressed cancer cell proliferation and colony formation in vitro. When transfected cancer cells were implanted into nude mice, the cells that overexpressed miR-137 grew more slowly and formed smaller tumors (P < 0.05) than vector transfectants. Histologically, xenograft tumors from cancer cells expressing miR-137 were less proliferative (P < 0.05), partly due to inhibition of EZH2 and LSD1 expression (P < 0.01) in both the transfected cancer cells and tumors. Reporter assays indicated that miR-137 targets EZH2 and LSD1. These results suggest that miR-137 is a tumor suppressor that is repressed in endometrial cancer because the promoter of its gene becomes hypermethylated.

UR - http://www.scopus.com/inward/record.url?scp=85049129398&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85049129398&partnerID=8YFLogxK

U2 - 10.1038/s41374-018-0092-x

DO - 10.1038/s41374-018-0092-x

M3 - Article

C2 - 29955087

AN - SCOPUS:85049129398

SP - 1

EP - 11

JO - Laboratory Investigation

JF - Laboratory Investigation

SN - 0023-6837

ER -